Skip to content

Slim honey in Obesity

An Open Label, Single Arm, Prospective Clinical Study To Evaluate Efficacy And Safety Of Slim Honey In Obese Subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/08/027196
Enrollment
30
Registered
2020-08-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases

Interventions

Intervention1: Slim Honey: 10 gm (1Tsp) of Slim Honey twice a day Morning and Evening for a period of 45 days Control Intervention1: Not Applicable: Not Applicable

Sponsors

Royal Bee Natural Products Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and/or female volunteers aged between 18 to 65 years both inclusive. 2. BMI ( >) greater than or equal to 25 kg/m2 and less than or equal to ( 3. Willing to do exercise for a span of 30 minutes daily for at least5 days in a week. 4. Willing to follow diet advised by investigator 5. Willing to come for regular follow-up visits.

Exclusion criteria

Exclusion criteria: 1. Intake of over the counter weight loss agents, centrally acting appetite suppressants or prior surgery for obesity in the previous three months. 2. History of pathophysiologic/genetic syndromes associated with obesity (Cushingâ??s syndrome, Turnerâ??s syndrome, and Parder- Willi Syndrome). 3. Alcoholics and subjects with substance abuse. 4. Subject with evidence of malignancy 5. Subjects having history of underlying inflammatory arthropathy, septic arthritis, inflammatory joint disease, gout, pseudo gout, Pagetâ??s disease, joint fracture, acromegaly, fibromyalgia, rheumatoid arthritis. 6. Subjects having history of coagulopathies, cardiovascular diseases, asthma. 7. Subjects with HbAlc > 7 % and poorly controlled diabetes mellitus, poorly controlled hypertension. 8. TSH > 10 mIU/L and T3 and T4 higher than normal range. 9. Pregnant and lactating women. 10. Subjects with hepatic and renal failure. 11. Subjects on prolonged ( > 6 weeks) medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 12. Subjects with hypersensitivity to any one ingredient of the drugs. 13. Subjects who have participated in other trial within last 3 months. 14. Any other condition which the principal investigator thinks may jeopardize the study.

Design outcomes

Primary

MeasureTime frame
change in body weight (kg)Timepoint: 6 weeks

Secondary

MeasureTime frame
Change in anthropometric measurementsTimepoint: 6 weeks;Change in quality of lifeTimepoint: 6 weeks;Tolerability of drugsTimepoint: 6 weeks

Countries

India

Contacts

Public ContactPuneet Mittal

Mittal Ayurved Sansthan

puneetmittal@mittalayurved.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026